Genialis

AI-driven DDR biomarker to predict response to WEE1 inhibitors and improve patient stratification for DNA damage response therapies.

GenExpress provides integrative bioinformatics tools for analyzing protein-RNA interactions generated by CLIP and RNA-Seq methods.

Genialis adcID predicts real-world response to T-DXd using RNA-seq modeling that goes beyond target expression to capture ADC biology.

Genialis Supermodel uses RNA data to uncover cancer biology and configure biomarkers, improving treatment decisions and care.

Genialis shares updates on RNA biomarkers, including company news, events, awards, and team insights.

Delve into Genialis scientific publications for insights on RNA biomarker discovery and precision medicine, powered by machine learning and big data.

Scientific posters published by Genialis at events and conferences

Genialis has been named as a winner in Inc.'s 2023 Best in Business list in the AI and Data category, a prestigious award honoring the businesses that have made the greatest positive impact in their fields.

Genialis unraveling complex biology to find new ways to treat disease, today released Expressions Version 3.0 to accelerate clinical biomarker discovery.

Genialis announced the addition of several new team members as the company works to improve healthcare and deliver the best possible outcomes for patients, their families and communities

Genialis releases updates on RNA biomarker innovations, including partnerships, collaborations, and key achievements.

Genialis uses AI to advance precision medicine through healthcare innovation.

Genialis combines data science with healthcare to improve patient outcomes.

Genialis collaborations with academic and clinical partners support the development and validation of RNA biomarkers for precision oncology.

Genialis develops new-generation clinical biomarkers using patient samples from around the world to predict treatment responses and support better decision-making for targeted therapies, immunotherapies, and other novel treatments.

Genialis is a precision oncology company helping the most promising molecules become life-saving medicines

Genialis uses biology-first AI to derive actionable cancer insights from limited patient data. The company presents ESMO data from three small clinical trial cohorts and a 25-month analysis of GitLab co-founder Sid Sijbrandij’s osteosarcoma case. These findings illustrate how AI-driven models can uncover patterns even in sparse datasets, advancing precision oncology.

Oct 2026GenialisNews article

Genialis partners with Inventia Life Science to combine **Genialis Supermodel** with **Inventia’s RASTRUM 3D cell model platform**, enabling therapeutic testing in pancreatic cancer models that reflect the biology of specific patient groups. The collaboration aims to bridge patient-specific data with advanced 3D tumor modeling for precision oncology research.

Sep 2026GenialisNews article

Genialis introduces **BioBridge**, a platform leveraging supermodel-powered tumor biology translation to bridge gaps in global drug development. The tool helps evaluate and reduce risks for oncology drugs originating from China, facilitating cross-population asset licensing. This addresses a key challenge in international collaboration for cancer therapies.

Jun 2026GenialisNews article

Genialis’s AI-powered **Supermodel** RNA survival model demonstrates superior accuracy over standard methods in predicting patient responses to **HER2-targeted therapy Enhertu**, using real-world clinical data. The model establishes a scalable biomarker framework for antibody-drug conjugate (ADC) drug development. Presented at **AACR 2026**, the findings highlight its potential to refine precision oncology approaches.

Apr 2026GenialisNews article